NCT00004182View on ClinicalTrials.gov

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 1999

Primary Completion Date

April 30, 2000

Study Completion Date

April 30, 2000

Conditions
Breast Cancer
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (2)

60611

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

94305-5408

Stanford University Medical Center, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00004182 - Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer | Biotech Hunter | Biotech Hunter